Sionna Therapeutics, Inc. - Common Stock (SION)

This company has had plenty of setbacks in recent years, but it generally bounces back.

They could both outperform the market over the medium term, but one appears to have a clear edge.

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

The drugmaker should significantly mitigate its most important risk as it develops new products.

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION) shares rose

Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis. The company also reported

This risk is weighing on the stock.

This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.

This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.

This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.

Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025.

AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology, and Singapore-based med-tech Basel Medical all made their public debuts this week.

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a modest opening, just slightly higher than its initial pricing.